The invention pertains to novel cyclin dependent kinase inhibitors (cdks)
and specifically, but not exclusively, as inhibitors of cdk/cyclin
complexes. As described herein, the inhibitors of this invention are
capable of inhibiting the cell-cycle machinery and consequently may be
useful in modulating cell-cycle progression, ultimately controlling cell
growth and differentiation. Such compounds would be useful for treating
subjects having disorders associated with excessive cell proliferation.
